BioXcel completes enrollment (last patient last visit) in SERENITY At-Home Phase 3 trial for BXCL501

BioXcel Therapeutics, Inc.

SERENITY At-Home Phase 3 safety trial for BXCL501 120 mcg to treat acute agitation in bipolar/schizophrenia.
Enrolled >200 patients across 22 sites; no single site >11% of total patients.
Patient distribution balanced between bipolar disorders and schizophrenia.
Collected data from >2,200 agitation episodes; topline results expected in August 2025.
Topline results expected to be announced this month.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.